MONTREAL, QUEBEC--(Marketwire - December 10, 2007) - ProMetic Life Sciences Inc. (TSX: PLI) (“ProMetic”) announces that a Phase II trial of its investigational compound PBI-1402 induced a significant increase in red blood cell count and hemoglobin level in patients with chemotherapy-induced anemia (“CIA”). Additionally, no significant adverse events were observed. PBI-1402 is a novel, orally active low molecular weight synthetic compound with erythropoiesis-stimulating activity via a mechanism of action distinct from erythropoietin (“EPO”). These results were presented in a poster session today at the American Society of Hematology 49th Annual Meeting in Atlanta.
